NEW YORK, May 14, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) between August 6, 2014 and April 23, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. If you purchased or otherwise acquired Aerie Pharmaceuticals, Inc. ("Aerie Pharmaceuticals") securities between August 6, 2014 and April 23, 2015, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Aerie Pharmaceuticals made false and misleading statements and/or failed to disclose adverse information regarding the Company's prospects for Rhopressa.
On April 23, 2015, Aerie Pharmaceuticals issued a release announcing that Rhopressa did not meet its "primary efficacy endpoint" in its first Phase 3 registration trial. Upon this news, shares of Aerie Pharmaceuticals fell more than 60 percent to close at $12.87 per share on April 24, 2015.
If you suffered a loss in Aerie Pharmaceuticals you have until June 29, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.